Bisphosphonates Might Get Limits On Treatment Duration Following Label Change

 
• By The Pink Sheet Daily

Accumulating data on femur fractures lead FDA to consider telling physicians to take patients off the drug at least temporarily when bone mineral density targets are reached.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet